Those familiar with the companies' thinking

Quote






Not going to happen. They have been shopping it but markets are tight and to be honest not a very compelling story as the fundamental issue continues to be market share position - they aren't winning where it matters - in the market and with customers.
 












It will take more bold steps by the new upper management to make this thing work. Many of the Directors and VPs have been around for years. If they have not got the job done it is time to move on. If the company is not efficient enough it needs to be consolidated into more efficient business units.

Not that anything will happen. WP seems to put up with easy as you go small baby steps. If that is what WP wants then just ignore this company as it is not going to be a major player in the ophthalmic business or an interesting IPO or buy for a company even in 2014.
 






no ipo.

i don't think the company can get the evaluation they'd want to IPO this.
anyone familiar with sector would rain on the parade and investors would stay away. Why buy a B&L IPO when you can buy allergan with great growth and a known history.

since it is private, hard to tell what the real numbers are on this place, can only go by past numbers and growth. which by all accounts has been stagnant across the board or anemic at best in some areas.

from 2007 when warburg bought out B&L.
"As an international company, almost 60% of its $2.3 billion annual revenue comes from outside of the United States. In its consumer divisions, which represents 49 percent of the company's revenue."

not a great story to have to tell. 60% expose to international markets which are imploding around the globe. 50% revenue from CL division which is losing share...

Anyone that dug into B&L history and numbers would not recommend this IPO to customers. I would not buy B&L stock knowing this sector, the company performance and international exposure.

sale much more likely than IPO at this point. I think warburg sits on this and sucks out cash to pay down debt. It's a job. somewhat stable but Not a very rewarding one given the culture and the executive management in place. really nasty micro management and the director in the west is a nightmare to work for.
seek employment elsewhere. You will be much happier.
 






The big problem with delaying the IPO is that there is likely nothing in the pipeline. The longer they wait for an IPO or sale the more obsolete the products get.

I agree. knowing this sector no one will commit big money for this thing.
 












Anonymous said:
The silly strategy of planting self-promoting articles in the WSJ and magazines will do nothing to help this company.
Click to expand...

It is pretty funny the way they do this. It is planted in the WSJ and then other news agencies pick it up as well. WSJ said IPO filed by end of summer. Makes company look good for possible sale. Ooops. Does not happen because company really isn't good enough for IPO.

Or how about a nice article on how the CEO is a miracle worker and turned around a troubled company in a few months. A true superman if you read the article. Too bad the company really is just a train wreck as if the CEO was a superman the company would be sold by now.

A real article would talk about market share. Ooops. No change there. No real turn around.
 






This is so sad to see - a truly great company run right into the ground. Current leadership team has no idea what to do but wait and hope for someone to buy - but anyone that takes even the most basic look can see what the real truth is...

Products that do get approved aren't able to be launched, and products that actually do get launched don't even make a dent in the marketplace as they are the fourth player, with a me-too product no less, to the game in a crowded market that B&L doesn't seem to understand.

After all these years undre WP the story is the same -- B&L moving sideways or backwards while Alcon, Allergan, AMO and others move forward.

Most of the people that knew the industry and business left years ago (or were forced out) - the current crop of leaders (generation 3 since WP took over) all sit there and wonder how they got there and how to get out...
 












Anonymous said:
B&L.

Resume builder if you are in upper management and want to go to another pharma sector.

Resume killer if you are in the sales force and stuck in ophthalmics.
Click to expand...

Working at B+L it is all about building your resume. Make sure you spend all of your time getting as many publications and patents as possible and make sure that the company can not put you in a development project that just generates data for product submissions without publications.

Since the whole R&D is doing this do you wonder why product submissions are delayed and that products that are launched are sub-par. No dedication to the company means B+L money is spent building peoples resumes and not building products for sale and long-term health of the company. WP really got screwed and is still getting screwed by helping people succeed in the ophthalmic business by providing the funds to build their resumes for future success at another company.
 






Top Bottom
Back
Quote